HKUMed's global collaborative study finds single-dose baloxavir reduces household influenza transmission: The phase 3b, double-blind, randomised, placebo-controlled trial enrolled 1,457 influenza-positive index patients and 2,681 household contacts across 15 countries from 2019 to 2024.
